Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: An EORTC- HOVON randomized phase III study (06914)

2001

British Journal of Haematology , Volume 115 - Issue 4 p. 895- 902

Additional Metadata
Keywords	Cyclosporin A, Multidrug resistance (MDR), Multiple myeloma, Reversal of multidrug resistance (MDR)
Persistent URL	doi.org/10.1046/j.1365-2141.2001.03171.x, hdl.handle.net/1765/64854
Journal	British Journal of Haematology
Organisation	Department of Hematology
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Sonneveld, P., Suciu, S., Weijermans, P., Beksaç, M., Neuwirtova, R., Solbu, G., Lokhorst, H., van der Lelie, J., Döhner, H., Gerhartz, H., Segeren, C., Willemze, R.& Löwenberg, B. (2001). Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: An EORTC- HOVON randomized phase III study (06914). British Journal of Haematology, 115(4), 895–902.https://doi.org/10.1046/j.1365-2141.2001.03171.x

Publication